Neoleukin Therapeutics, Inc. is a clinical‐stage biotechnology company that specializes in the design and development of de novo protein therapeutics for cancer and immune‐related diseases. By leveraging proprietary computational design and high‐throughput screening technologies, the company builds novel protein scaffolds that mimic or improve upon natural cytokines, offering enhanced receptor selectivity, stability, and pharmacokinetic profiles. Neoleukin’s platform is built to generate next‐generation immunotherapies with the potential to address unmet medical needs in oncology and beyond.
The company’s lead candidate, NL-201, is a hyper‐stable cytokine receptor agonist designed to selectively engage the IL-2 and IL-15 pathways without reliance on the native cytokines’ structure. NL-201 is currently in early‐phase clinical trials for patients with advanced solid tumors, both as a monotherapy and in combination with immune checkpoint inhibitors. In addition to NL-201, Neoleukin is advancing a preclinical pipeline of novel cytokine mimetics and immune modulators aimed at broadening the therapeutic reach of its de novo proteins across multiple disease settings.
Neoleukin Therapeutics was founded in 2015 as a spinout from leading academic laboratories in protein engineering and computational biology. Headquartered in Seattle, Washington, the company maintains research and development operations in the United States and collaborates with contract manufacturing organizations to support its clinical programs. Since its initial public offering in 2019, Neoleukin has expanded its workforce of structural biologists, immunologists, and bioprocess engineers to drive discovery and development activities forward.
The company is led by a seasoned management team with deep expertise in biotechnology and drug development. David Grayzel, chief executive officer, brings over two decades of experience in translational research and portfolio management, while the scientific leadership team combines backgrounds in immunology, bioinformatics, and protein design. Neoleukin also collaborates with academic institutions and strategic partners to accelerate its pipeline and explore novel applications of its de novo protein technology.
AI Generated. May Contain Errors.
